Get the Stockscreener App
3.625
0.69%
0.025
After Hours:
3.51
-0.115
-3.17%
Atea Pharmaceuticals Inc stock is traded at $3.625, with a volume of 474.19K.
It is up +0.69% in the last 24 hours and up +16.94% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.60
Open:
$3.59
24h Volume:
474.19K
Relative Volume:
1.20
Market Cap:
$275.57M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.7512
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
+4.47%
1M Performance:
+16.94%
6M Performance:
+5.99%
1Y Performance:
+12.23%
1-Day Range:
$3.59
$3.80
1-Week Range:
$3.425
$3.80
52-Week Range:
$2.455
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.625 | 275.57M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance
Bank of America Corp DE Boosts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Millennium Management LLC Invests $75,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Squarepoint Ops LLC Buys 35,053 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Two Sigma Investments LP - Defense World
Jane Street Group LLC Decreases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Public Employees Retirement System of Ohio Trims Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Ameriprise Financial Inc. Sells 11,900 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
ProShare Advisors LLC Buys 6,163 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
BNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Northern Trust Corp Boosts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
D. E. Shaw & Co. Inc. Purchases 62,505 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World
Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World
Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com
Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Wells Fargo & Company MN Increases Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals (AVIR) to Release Earnings on Monday - Defense World
Atea reports high efficacy in Phase 2 HCV drug trial By Investing.com - Investing.com Nigeria
Barclays PLC Increases Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals (AVIR) Reveals Promising Phase 2 Results for Hepatitis C Treatment | AVIR Stock News - GuruFocus
Atea reports high efficacy in Phase 2 HCV drug trial - Investing.com
Atea Pharmaceuticals Announces Full Results from Phase 2 - GlobeNewswire
Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025 - marketscreener.com
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - Stock Titan
A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com
Atea Pharmaceuticals (AVIR) Organizes HCV Treatment Panel & Announces Q1 Results | AVIR Stock News - GuruFocus
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times
JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com
Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX
Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World
Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada
Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP
Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz
Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks
Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com
Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks
Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):